RGNX Quote, Financials, Valuation and Earnings

Krystal Biotech, Inc. has a net margin of -221.34% compared to REGENXBIO, Inc.'s net margin of 47.99%. REGENXBIO, Inc.'s return on equity of -95.82% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

REGENXBIO, Inc. has a consensus price target of $27.82, signalling upside risk potential of 226.12%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $314.00 which suggests that it could grow by 20.33%. Given that REGENXBIO, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe REGENXBIO, Inc. is more attractive than Krystal Biotech, Inc..

REGENXBIO, Inc. has a beta of 1.137, which suggesting that the stock is 13.687% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.540, suggesting its less volatile than the S&P 500 by 46.017%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $30.3M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $107.1M. REGENXBIO, Inc.'s net income of -$67.1M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 38.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.55x versus 20.22x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -221.34% compared to REGENXBIO, Inc.'s net margin of -1144.46%. REGENXBIO, Inc.'s return on equity of -95.82% beat Ocugen, Inc.'s return on equity of -848.82%.

REGENXBIO, Inc. has a consensus price target of $27.82, signalling upside risk potential of 226.12%. On the other hand Ocugen, Inc. has an analysts' consensus of $11.57 which suggests that it could grow by 546.45%. Given that Ocugen, Inc. has higher upside potential than REGENXBIO, Inc., analysts believe Ocugen, Inc. is more attractive than REGENXBIO, Inc..

REGENXBIO, Inc. has a beta of 1.137, which suggesting that the stock is 13.687% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.305%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $30.3M, which are larger than Ocugen, Inc. quarterly revenues of -$193K. REGENXBIO, Inc.'s net income of -$67.1M is lower than Ocugen, Inc.'s net income of -$17.7M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.55x versus 121.39x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of -221.34% compared to REGENXBIO, Inc.'s net margin of --. REGENXBIO, Inc.'s return on equity of -95.82% beat Replimune Group, Inc.'s return on equity of -92.13%.

REGENXBIO, Inc. has a consensus price target of $27.82, signalling upside risk potential of 226.12%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.86 which suggests that it could grow by 52.88%. Given that REGENXBIO, Inc. has higher upside potential than Replimune Group, Inc., analysts believe REGENXBIO, Inc. is more attractive than Replimune Group, Inc..

REGENXBIO, Inc. has a beta of 1.137, which suggesting that the stock is 13.687% more volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.18%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $30.3M, which are larger than Replimune Group, Inc. quarterly revenues of --. REGENXBIO, Inc.'s net income of -$67.1M is higher than Replimune Group, Inc.'s net income of -$70.9M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.55x versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -221.34% compared to REGENXBIO, Inc.'s net margin of -93.07%. REGENXBIO, Inc.'s return on equity of -95.82% beat Sarepta Therapeutics, Inc.'s return on equity of -64.94%.

REGENXBIO, Inc. has a consensus price target of $27.82, signalling upside risk potential of 226.12%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.65 which suggests that it could fall by -6.79%. Given that REGENXBIO, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe REGENXBIO, Inc. is more attractive than Sarepta Therapeutics, Inc..

REGENXBIO, Inc. has a beta of 1.137, which suggesting that the stock is 13.687% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.103%.

REGENXBIO, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. REGENXBIO, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

REGENXBIO, Inc. quarterly revenues are $30.3M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $442.9M. REGENXBIO, Inc.'s net income of -$67.1M is higher than Sarepta Therapeutics, Inc.'s net income of -$412.2M. Notably, REGENXBIO, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for REGENXBIO, Inc. is 2.55x versus 1.08x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.